Syros Pharmaceuticals (SYRS) Price & Analysis

Q: What was Syros Pharmaceuticals’s price range in the past 12 months?

Syros Pharmaceuticals lowest stock price was <$0.01 and its highest was $3.40 in the past 12 months.

Q: What is Syros Pharmaceuticals’s market cap?

Syros Pharmaceuticals’s market cap is $16.10K.

Q: When is Syros Pharmaceuticals’s upcoming earnings report date?

Syros Pharmaceuticals’s upcoming earnings report date is Nov 18, 2025 which is in 10 days.

Q: Is Syros Pharmaceuticals overvalued?

According to Wall Street analysts Syros Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Syros Pharmaceuticals pay dividends?

Syros Pharmaceuticals does not currently pay dividends.

Q: What is Syros Pharmaceuticals’s EPS estimate?

Syros Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Syros Pharmaceuticals have?

Syros Pharmaceuticals has 26,832,457 shares outstanding.

Q: Which hedge fund is a major shareholder of Syros Pharmaceuticals?

Currently, no hedge funds are holding shares in SYRS

Compare

1,074 Followers

SYRS Stock Chart & Stats

$0.02

-$0.03(-11.29%)

At close: Jan 08 4:00 PM EST

$0.02

-$0.03(-11.29%)

Day’s Range― - ―

52-Week Range<$0.01 - $3.40

Previous CloseN/A

Volume1.14M

Average Volume (3M)98.49K

Market Cap

$16.10K

Enterprise Value$86.52M

Total Cash (Recent Filing)$58.27M

Total Debt (Recent Filing)$60.23M

Price to Earnings (P/E)―

Beta8.88

Next Earnings

Nov 18, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding26,832,457

10 Day Avg. Volume38,912

30 Day Avg. Volume98,487

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)13.24

Price to Sales (P/S)22.21

P/FCF Ratio-2.01

Enterprise Value/Market Cap5.37K

Enterprise Value/Revenue224.15

Enterprise Value/Gross Profit-97.99

Enterprise Value/Ebitda-0.95

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Drug TolerabilityThe tamibarotene/azacitidine combination was well-tolerated, with an adverse event profile reflective of prior clinical trials.

Bears Say

Analyst OpinionSyros Pharmaceuticals has been downgraded from Buy to Neutral with a price target reduced from $6 to $1.

Clinical TrialsThe failure of SELECT-MDS-1 ends Syros' last active clinical program and triggers an event of default under the terms of the company's secured loan facility with Oxford Finance.

Financial PerformanceThe stock traded down about 86% in the aftermarket, reflecting a significant decline in valuation.

Syros Pharmaceuticals News

Six new option listings and option delistings on October 20th

New option listings for October 20th include Tradr 2X Long AUR Daily ETF (AURU), Tradr 2X Long CELH...

19d ago

CLPS

FLOT

Is SYRS a Buy, Before Earnings?

Syros Pharmaceuticals (SYRS) is scheduled to report 1st quarter earnings on 05/01/2025. Regarding Q1 estimates, Wall Street analysts...

6M ago

SYRS

Syros Pharmaceuticals sells Tamibarotene assets to Rege Nephro

Rege Nephro has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals (SYRS),...

7M ago

SYRS

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

8M ago

ACIU

ADMA

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

8M ago

ADMA

ALDX

Is SYRS a Buy, Before Earnings?

Syros Pharmaceuticals (SYRS) is scheduled to report 4th quarter earnings on 03/06/2025. Regarding Q4 estimates, Wall Street analysts...

8M ago

SYRS

Syros Pharmaceuticals Delists from Nasdaq Amid Restructuring

Syros Pharmaceuticals ( ($SYRS) ) has issued an update. On February 28, 2025, Syros Pharmaceuticals announced its decision...

8M ago

SYRS

Syros Pharmaceuticals trading resumes

16:35 EST Syros Pharmaceuticals (SYRS) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

8M ago

SYRS

Syros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stock

Syros Pharmaceuticals (SYRS) announced that its Board of Directors has approved and the company intends to proceed with...

8M ago

SYRS

Syros Pharmaceuticals trading halted, news pending

16:00 EST Syros Pharmaceuticals (SYRS) trading halted, news pending Published first on TheFly – the ultimate source for...

8M ago

SYRS

Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges

Syros Pharmaceuticals ( ($SYRS) ) has shared an announcement. Syros Pharmaceuticals faces significant challenges as it terminates its...

12M ago

SYRS

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

12M ago

ALT

NVS

Syros Pharmaceuticals downgraded to Hold from Buy at TD Cowen

TD Cowen analyst Phil Nadeau downgraded Syros Pharmaceuticals (SYRS) to Hold from Buy after the company announced that...

12M ago

SYRS

Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Syros Pharmaceuticals (SYRS) to Neutral from Buy with a price target of $1, down from...

12M ago

SYRS

SYRS FAQ

What was Syros Pharmaceuticals’s price range in the past 12 months?

Syros Pharmaceuticals lowest stock price was <$0.01 and its highest was $3.40 in the past 12 months.

What is Syros Pharmaceuticals’s market cap?

Syros Pharmaceuticals’s market cap is $16.10K.

When is Syros Pharmaceuticals’s upcoming earnings report date?

Syros Pharmaceuticals’s upcoming earnings report date is Nov 18, 2025 which is in 10 days.

How were Syros Pharmaceuticals’s earnings last quarter?

Currently, no data Available

Is Syros Pharmaceuticals overvalued?

According to Wall Street analysts Syros Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Syros Pharmaceuticals pay dividends?

Syros Pharmaceuticals does not currently pay dividends.

What is Syros Pharmaceuticals’s EPS estimate?

Syros Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Syros Pharmaceuticals have?

Syros Pharmaceuticals has 26,832,457 shares outstanding.

What happened to Syros Pharmaceuticals’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Syros Pharmaceuticals?

Currently, no hedge funds are holding shares in SYRS

Company Description

Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines to treat cancer and other serious diseases. The company leverages its proprietary gene control platform to discover and develop therapies that modulate gene expression. Syros' lead product candidates include tamibarotene, a selective retinoic acid receptor alpha (RARα) agonist for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and SY-5609, a selective CDK7 inhibitor for the treatment of select solid tumors.